Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2025)
10 slides from Immuron's shareholder meeting presentation, Nov 12, 2025
Slide 1: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to
Slide 2: Immuron
© Immuren —_ :
Slide 3: AGM Presentation 11 November 2025
AGM PRESENTATION 11 NOVEMBER 2025 S teve n Lyde a m ore - C EO NASDAQ: IMRN ASX: IMC
Slide 4: Forward-looking statements notice
2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intend
Slide 5: Immuron: Australian integrated biopharmaceutical company
3 Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases Research & Development 3 pipeline assets in 2 clinical programmes Global footprint Australia, US, Canada and exp
Slide 6: FY25 Financial Achievements
8 FY25 Financial Achievements Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex - R&D) 1 $(3.1)m $2.1m improvement Cash + Term Deposit 2,3 $5.9m 1 ex - R&D: add back research & development, less R&D
Slide 7: Travelan continued strong sales growth
5 Travelan® continued strong sales growth Global + FY2025 AUD$7.3 million up 49% on prior year + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 Australia + FY2025 AUD$5.2 million up 40% on prior year + FY2026 AUD$1.6 million up 52% on FY2025 Q1 North America + FY2025 AUD$2.0 million up 76% on prior y
Slide 8: FY25 Clinical Achievements and Operational Highlights
6 FY25 Clinical Achievements and Operational Highlights FDA approval IMM - 529 IND Travelan® n= 851 trial completed Travelan® Ph 2 statistically significant results 1 New research collaboration IMM - 986 (VRE) New product launch in Australia Updated peak U.S. sales for IMM - 529 US$400 million 2 1.
Slide 9: FY26 Outlook
7 FY26 Outlook Continued YoY sales growth Progression towards EBITDA (ex - R&D) 1 breakeven Travelan® n=851 trial topline data November 2025 IMM - 986 (VRE) Pre - clinical data 1H 2026 Travelan® End of Phase 2 Meeting with FDA 1H 2026 IMM - 529 Initiation of Phase 2 1H 2026 1 ex - R&D: add back rese
Slide 10: Steven Lydeamore, Chief Executive Officer: Contact Information
STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 IMMURON I NVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH